Abstract:INTRODUCTION AND OBJECTIVES: Docetaxel (DTX) is one of the primary drugs used for treating castration resistant prostate cancer (CRPC).Unfortunately, over time patients invariably develop resistance to DTX therapy and their disease will continue to progress.The mechanisms by which resistance develops is still incompletely understood.This study seeks to determine the involvement of miRNAs, specifically miR-181a, in DTX resistance in CRPC.METHODS: Total RNA from parental C4-2B prostate cancer cells and DTX resistant C4-2B cells (C4-2B TaxR) was submitted for small RNA deep sequencing.Data was analyzed to ascertain which miRNAs expressions were most altered in C4-2B TaxR cells compared to parental cells.Having identified an increase in miR-181a in resistant cells, its expression was modulated in C4-2B and C4-2B TaxR cells by transfecting them with miR-181a mimics or antisense, respectively.Following transfection, cell number was determined after 48 h with or without DTX.Cross resistance to cabazitaxel induced by miR-181a was also determined.Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity.Phospho-p53 expression was assessed by western blot and apoptosis was measured by ELISA in C4-2B TaxR cells with inhibited miR-181a expression with or without DTX.RESULTS: miR-181a is significantly upregulated in C4-2B TaxR cells compared to parental C4-2B cells as analyzed by small RNA sequencing.Overexpression of miR-181a in C4-2B cells confers DTX and cabazitaxel resistance.Knockdown of miR-181a in C4-2B TaxR cells re-sensitizes them to treatment with both DTX and cabazitaxel.miR-181a knockdown alone induced apoptosis in C4-2B TaxR cells which is further enhanced by DTX.We next assessed if miR-181a altered expression or activity of ABCB1, which is overexpressed/active in C4-2B TaxR cells and promotes resistance to DTX by pumping the drug out of cells.We found that miR-181a does not impact ABCB1 expression or activity.Since we previously demonstrated that phospho-p53 can modulate DTX sensitivity, we determined if miR-181a can alter p53 expression in C4-2B TaxR cells.Knockdown of miR-181a in C4-2B TaxR cells induced phospho-p53 expression, suggesting that miR-181a induced resistance to DTX is mediated by inhibition of phospho-p53 expression.CONCLUSIONS: Overexpression of mir-181a in C4-2B TaxR cells contributes to their resistance to DTX and inhibition of mir-181a expression can restore treatment response.This is due, in part, to modulation of p53 phosphorylation and induction of apoptosis.

HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9.

Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells

MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells Via Direct Suppression of JAG1/Notch1 Axis

Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Hdac 1/4-Mediated Silencing of Microrna-200b Promotes Chemoresistance in Human Lung Adenocarcinoma Cells

miR-145-5p Inhibits Neuroendocrine Differentiation and Tumor Growth by Regulating the SOX11/MYCN Axis in Prostate cancer

A Trio of Tumor Suppressor Mirna Downregulates CREB5 Dependent Transcription to Modulate Neoadjuvant Hormonal Therapy Sensitivity.

MiR-138–5p Inhibits Prostate Cancer Cell Proliferation and Chemoresistance by Targeting APOBEC3B

Targeting the Neddylation Pathway to Suppress the Growth of Prostate Cancer Cells: Therapeutic Implication for the Men’s Cancer

Acquisition of Radioresistance in Docetaxel-Resistant Human Lung Adenocarcinoma Cells is Linked with Dysregulation of Mir-451/C-myc-survivin/rad-51 Signaling

Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling.

MicroRNA‐1 overexpression increases chemosensitivity of non‐small cell lung cancer cells by inhibiting autophagy related 3‐mediated autophagy

MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis

MicroRNA-451 Induces Epithelial–mesenchymal Transition in Docetaxel-Resistant Lung Adenocarcinoma Cells by Targeting Proto-Oncogene C-Myc

miR-541-3p enhances the radiosensitivity of prostate cancer cells by inhibiting HSP27 expression and downregulating -catenin

MP99-17 CIRCULARRNA-C17 ALTERS THE ANTI ANDROGEN-ENZALUTAMIDE RESISTANCE IN CASTRATION-RESISTANT PROSTATE CANCER VIA REGULATING ANDROGEN RECEPTOR VARIANT ARV7 EXPRESSION

Use of Mir-145 and Testicular Nuclear Receptor 4 Inhibition to Reduce Chemoresistance to Docetaxel in Prostate Cancer

CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer

Silencing of CDC20 Suppresses Metastatic Castration-Resistant Prostate Cancer Growth and Enhances Chemosensitivity to Docetaxel.

Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer